Lincoln Pharma Aims for Rs 1000 Crore Revenue
Lincoln Pharmaceuticals Ltd announces ambitious plan to achieve Rs 1000 crore revenue within three years through strategic expansion and new product launches. Read more about their growth strategy.
Category : Search result: Piramal Pharma
Anand Piramal's Tribute to Nita Ambani at NSE Listing
Anand Piramal's emotional tribute to mother-in-law Nita Ambani highlighted the Piramal Finance NSE listing. A major merger milestone for the corporate giant. Read more.
OneSource Pharma Raises FY28 Revenue Target to $500M
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Gujarat Pharma Factory Blast: 2 Dead, 20 Injured
Tragic boiler explosion at pharmaceutical factory in Gujarat's Bharuch district claims 2 lives, leaves 20 injured. Massive fire brought under control by emergency teams.
India's Drug Regulator Tightens Pharma Quality Control
India's DCGI orders nationwide inspections of small pharma units as WHO flags toxic cough syrups. MSMEs struggle to meet new Schedule M compliance deadline of January 2026.
Indian Pharma Units Face Closure Over GMP Non-Compliance
DCGI directs state authorities to enforce strict GMP compliance by December 31, 2025. Delhi, Himachal Pradesh, Uttarakhand already taking action against non-compliant manufacturers.
DCGI Orders Global Pharma Standards Implementation by Jan 2026
India's drug regulator DCGI mandates global manufacturing standards for all pharma companies by January 2026. State regulators ordered to begin inspections immediately. Read about the strict compliance requirements.
Sun Pharma: US Tariff Clarity & Q2 FY26 Outlook
Sun Pharma investors await Q2 FY26 results with cautious optimism as US tariff clarity emerges. Discover how import duties and market dynamics could impact India's pharmaceutical giant.
Indian Pharma Soars with Record US Generic Drug Profits
Indian pharmaceutical companies are reporting exceptional earnings driven by US generic drug sales, leading to major fundraising initiatives for expansion into medtech and wellness sectors.
AstraZeneca Q3 Profit Jumps 77% to $2.53 Billion
British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.
Piramal Pharma Bets on US Biopharma Funding Revival
Piramal Pharma anticipates significant growth as US biopharma funding shows recovery signs, with CDMO business poised for major expansion.
Piramal Finance Gets Abu Dhabi Investment Boost
Jairam Sridharan-led Piramal Finance secures strategic foreign investment from Abu Dhabi's International Holding Company and Samman Capital, signaling strong global confidence in India's NBFC sector.
Solara Pharma Q2 Loss: ₹10 Crore Amid Challenges
Solara Active Pharma Sciences faces challenging quarter with ₹10 crore net loss despite revenue growth. Discover the operational challenges and management's recovery strategy.
Sun Pharma Q2 Profit Rises 2.5% to ₹3,118 Crore
India's pharmaceutical giant Sun Pharma reports steady Q2 growth with 9% revenue increase while navigating US market challenges. Key insights from their latest earnings report.
Navin Fluorine Shares Surge 22% in 3 Sessions
Discover why Navin Fluorine International shares skyrocketed 22% in just three trading sessions. Expert analysis reveals the key drivers behind this chemical sector powerhouse's impressive rally and what investors should watch next.
Q2 Results Today: Sun Pharma, Grasim, Britannia Earnings
Market eyes Wednesday's Q2 earnings bonanza as pharma giant Sun Pharma, Grasim Industries, and FMCG major Britannia declare results. Get complete analysis and investor expectations.
3 Hot Stocks: Grasim, Aurobindo Pharma, City Union Bank
Religare Broking's Ajit Mishra reveals 3 promising stocks for short-term gains. Discover technical analysis and price targets for Grasim, Aurobindo Pharma, and City Union Bank in this exclusive market insight.
Hot Stocks: Oil India, Aurobindo Pharma, Latent View Analysis
Get expert stock market insights from Jigar Patel of Anand Rathi as he reveals why Oil India, Aurobindo Pharma, and Latent View Analytics present compelling short-term opportunities for Indian investors.
Health Biotech Expands Global Presence at CPhI Frankfurt
Indian biopharmaceutical leader Health Biotech Limited makes waves at CPhI Frankfurt 2025, showcasing innovative products and forging international partnerships to strengthen its global market position.
Niner Pharma Expands R&D with 125 New Peptide Molecules
Chandigarh-based Niner Pharma announces massive R&D expansion with 125 novel peptide molecules targeting wellness and cosmetic innovation, positioning India as global leader in peptide research.
Cipla Shares Fall 4% After Q2 Results
Cipla's stock faced significant pressure after Q2 FY2025 results revealed margin pressures despite revenue growth. Discover the key factors behind the 4% decline and what analysts are saying about the pharmaceutical giant's future prospects.
US Push for Affordable Biotech Drugs: India's Opportunity
Federal health officials are accelerating efforts to bring cheaper biotech drugs to market, potentially transforming treatment access and creating new opportunities for Indian pharmaceutical companies.
India Bans Fraudulent Pharma Licenses in Major Reform
India implements sweeping regulatory reforms to combat fraudulent pharmaceutical manufacturing licenses, enhancing drug safety standards for domestic and international markets including US and EU.
Mukul Agrawal's ₹200 Cr Pharma Stock Bet Revealed
Discover why prominent investor Mukul Agrawal is betting big on a small-cap pharma company with massive growth potential. Get exclusive insights into his latest portfolio move and what it means for retail investors.
Dr. Reddy's Legacy: Transforming Indian Pharma
Discover how Dr. Anji Reddy's visionary journey from generics to innovative drug research positioned India as a global pharmaceutical powerhouse and continues to inspire future generations.
Bangladeshi generic drug slashes rare disease treatment cost by 96%
In a revolutionary healthcare development, Bangladesh's Beximco Pharma launches affordable generic version of lifesaving rare disease drug, dramatically reducing treatment costs from crores to lakhs for patients across South Asia.
Sigachi Q2: Profit Halves, Revenue Down 19%
Sigachi Industries faces turbulent quarter with net profit crashing to ₹10.5 crore amid significant revenue decline. What's behind the pharmaceutical giant's disappointing performance?
Cipla Shares Fall 3% Despite Eli Lilly Weight Loss Drug Deal
Cipla's stock faces unexpected pressure despite securing rights to manufacture and distribute Eli Lilly's revolutionary weight loss drug Mounjaro in India. Discover why investors remain cautious.
Cipla-Eli Lilly deal brings weight loss drugs to India
Indian pharmaceutical giant Cipla announces landmark deal with Eli Lilly to manufacture and distribute popular weight loss medications Mounjaro and Zepbound in India under different brand names.
Aurobindo Pharma Expands to Chile with New Subsidiary
Indian pharma giant Aurobindo Pharma establishes new subsidiary in Chile, marking strategic expansion across South American markets with focus on branded prescriptions and over-the-counter medicines.
Page 3 of 4